Furthermore, also carcinomas with a high expression of ErbB2, such as non-small cell lung carcinoma, gastric and prostatic tumours, have been found to be resistant or much less sensitive to Trastuzumab treatment (Agus et al, 1999; Gong et al, 2004). Here, ERBB2 is linked to carcinoma.